FY2025 · ended Dec 31, 2025 · Revenue $22,000 · Filed Mar 27, 2026
Senti Biosciences Holdings, Inc. (SNTI) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $22,000 and a net loss of $61.4 million. Free cash flow was -$43.6 million. As of Jun 30, 2026 it held $13.0 million in cash and investments and $16.2 million in total debt.
Revenue
$22,000
Net income (TTM)
$-49.56M
+15.0% vs year-ago TTM
Operating cash flow (TTM)
$-38.05M
+21.5% vs year-ago TTM
Free cash flow (TTM)
$-38.05M
+21.9% vs year-ago TTM
EPS (TTM)
$-1.72
+66.8% vs year-ago TTM
Dividend per share
None
Shares outstanding
31.14M
+0.0% vs prior year
Net cash
$-3.25M
as of Jun 30, 2026
Operating margin
-312631.8%
FY 2025
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- SNTI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1854270
- Former names
- Senti Biosciences, Inc. (until May 8, 2026); Senti Biosciences, Inc.\ (until Jun 28, 2022); Dynamics Special Purpose Corp. (until Jun 13, 2022)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $22,000 | $0 | $2.0M | $3.3M | — |
| Operating income | -$68.8M | -$61.0M | -$92.7M | -$62.1M | -$40.4M |
| Net income | -$61.4M | -$52.8M | -$71.1M | -$58.2M | -$55.3M |
| Diluted EPS | -$2.73 | -$12.03 | -$16.01 | -$2.23 | — |
| Operating cash flow | -$43.4M | -$41.4M | -$52.4M | -$34.9M | -$34.6M |
| Free cash flow | -$43.6M | -$41.4M | -$64.4M | -$76.3M | — |
| Total assets | $51.2M | $97.8M | $119.5M | $180.8M | $96.7M |
| Total liabilities | $45.6M | $47.1M | $52.6M | $53.5M | $36.3M |
| Stockholders' equity | $5.6M | $25.6M | $66.9M | $127.3M | -$111.5M |
| Cash and investments | $34.6M | $48.3M | $35.9M | $98.6M | $56.0M |
| Total debt | $28.9M | $33.6M | $37.7M | $37.1M | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Other events
|
Oct 27, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended, Acquisition or sale of assets, Unregistered share sale
|
Oct 26, 2026 | Oct 21, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Oct 15, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Other events
|
Oct 13, 2026 | Oct 8, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 24, 2026 | Sep 23, 2026 |
| 8-K |
Current report
Material agreement, New debt
|
Sep 4, 2026 | Sep 3, 2026 |
All 367 Senti Biosciences Holdings, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.